Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. more
Time Frame | MLYS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.31% | -1.57% | 0.94% |
1-Month Return | -9.55% | -1.86% | 5.38% |
3-Month Return | 2.35% | -6.07% | 10.61% |
6-Month Return | -9.41% | -0.47% | 13.65% |
1-Year Return | 79.71% | 10% | 33.13% |
3-Year Return | -23.62% | 10.67% | 32.44% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Profit | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 2.94M | 18.73M | 31.48M | 84.66M | [{"date":"2020-12-31","value":3.48,"profit":true},{"date":"2021-12-31","value":22.12,"profit":true},{"date":"2022-12-31","value":37.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (2.94M) | (18.73M) | (31.48M) | (84.66M) | [{"date":"2020-12-31","value":-294300000,"profit":false},{"date":"2021-12-31","value":-1872500000,"profit":false},{"date":"2022-12-31","value":-3147900000,"profit":false},{"date":"2023-12-31","value":-8465700000,"profit":false}] | |
Total Non-Operating Income/Expense | (598.00K) | (710.00K) | 1.68M | 23.13M | [{"date":"2020-12-31","value":-2.59,"profit":false},{"date":"2021-12-31","value":-3.07,"profit":false},{"date":"2022-12-31","value":7.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Pre-Tax Income | (3.43M) | (19.41M) | (29.80M) | (71.90M) | [{"date":"2020-12-31","value":-342600000,"profit":false},{"date":"2021-12-31","value":-1940800000,"profit":false},{"date":"2022-12-31","value":-2979900000,"profit":false},{"date":"2023-12-31","value":-7189800000,"profit":false}] | |
Income Taxes | 115.00K | 27.00K | (1.90M) | (167.90K) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":23.48,"profit":true},{"date":"2022-12-31","value":-1656.07,"profit":false},{"date":"2023-12-31","value":-146,"profit":false}] | |
Income After Taxes | (3.54M) | (19.43M) | (27.89M) | (71.73M) | [{"date":"2020-12-31","value":-354100000,"profit":false},{"date":"2021-12-31","value":-1943500000,"profit":false},{"date":"2022-12-31","value":-2789451500,"profit":false},{"date":"2023-12-31","value":-7173010500,"profit":false}] | |
Income From Continuous Operations | (3.43M) | (19.41M) | (29.80M) | (56.58M) | [{"date":"2020-12-31","value":-342600000,"profit":false},{"date":"2021-12-31","value":-1940800000,"profit":false},{"date":"2022-12-31","value":-2979900000,"profit":false},{"date":"2023-12-31","value":-5658200000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (3.43M) | (19.41M) | (29.80M) | (71.90M) | [{"date":"2020-12-31","value":-342600000,"profit":false},{"date":"2021-12-31","value":-1940800000,"profit":false},{"date":"2022-12-31","value":-2979900000,"profit":false},{"date":"2023-12-31","value":-7189800000,"profit":false}] | |
EPS (Diluted) | - | - | (1.74) | (2.00) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-174,"profit":false},{"date":"2023-12-31","value":-200,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
MLYS | |
---|---|
Cash Ratio | 8.42 |
Current Ratio | 8.55 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MLYS | |
---|---|
ROA (LTM) | -38.56% |
ROE (LTM) | -61.19% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MLYS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.12 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.88 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MLYS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.64 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Mineralys Therapeutics, Inc. Common Stock (MLYS) share price today is $12.22
Yes, Indians can buy shares of Mineralys Therapeutics, Inc. Common Stock (MLYS) on Vested. To buy Mineralys Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MLYS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Mineralys Therapeutics, Inc. Common Stock (MLYS) via the Vested app. You can start investing in Mineralys Therapeutics, Inc. Common Stock (MLYS) with a minimum investment of $1.
You can invest in shares of Mineralys Therapeutics, Inc. Common Stock (MLYS) via Vested in three simple steps:
The 52-week high price of Mineralys Therapeutics, Inc. Common Stock (MLYS) is $16.91. The 52-week low price of Mineralys Therapeutics, Inc. Common Stock (MLYS) is $6.65.
The price-to-earnings (P/E) ratio of Mineralys Therapeutics, Inc. Common Stock (MLYS) is
The price-to-book (P/B) ratio of Mineralys Therapeutics, Inc. Common Stock (MLYS) is 2.64
The dividend yield of Mineralys Therapeutics, Inc. Common Stock (MLYS) is 0.00%
The market capitalization of Mineralys Therapeutics, Inc. Common Stock (MLYS) is $624.60M
The stock symbol (or ticker) of Mineralys Therapeutics, Inc. Common Stock is MLYS